A study for evaluate bioavailability in healthy adults after the consumption of an component in eggs.

A study for evaluate bioavailability in healthy adults after the consumption of an component in eggs. - A study for evaluate bioavailability in healthy adults after the consumption of an component in eggs.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000038848

Enrollment

Registered

2019-12-12

Start date

2019-12-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy adults

Interventions

Oral ingestion of the test product one time. (3g:Consumption of an component in eggs) Oral ingestion of the test product one time. (2g:Consumption of an component in eggs) Oral ingestion of the tes

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Males and females aged 20 years and older Kewpie corporation member.Individuals who sign the consent document after explanation of this study. 2.Individuals who can stop routinely take proprietary drugs and health foods including beverages. 3.Subjects who can maintain an everyday lifestyle during study period constantly.

Exclusion criteria

Exclusion criteria: 1.Individuals who have serious hepatopathy, (e.g.diabetes mellitus,hepatic disorder,heart disease,renal disorder,cancer) and dyslipidemia,mental disorder. 2.Subjects who are diagnosed for anemia or have treatment history for anemia. 3.Subjects who are active mass (exercise) in everyday life. 4.Subjects who cause food and skin allergy symptoms by food and medicine. 5.Subjects who are pregnant, may be pregnant in near future, or are breast-feeding. 6.Others considered as inappropriate for the study by the physician.

Design outcomes

Primary

Measure	Time frame
plasma concentration of an component in eggs.(Phospholipid)	—

Countries

Japan

Contacts

Public ContactTatsuo Uetake

CXwellness, Inc. CEO

uetake@cx-wellness.com03-6225-5601

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026